Antares Pharma (ATRS) Gets a Buy Rating from H.C. Wainwright


H.C. Wainwright analyst Oren Livnat reiterated a Buy rating on Antares Pharma (ATRS) today and set a price target of $4.50. The company’s shares closed last Friday at $2.85.

According to TipRanks.com, Livnat is a 3-star analyst with an average return of 3.3% and a 45.6% success rate. Livnat covers the Healthcare sector, focusing on stocks such as Collegium Pharmaceutical, Taiwan Liposome Company, and Zynerba Pharmaceuticals.

Currently, the analyst consensus on Antares Pharma is a Moderate Buy with an average price target of $4.50, which is a 55.7% upside from current levels. In a report issued on November 2, Raymond James also maintained a Buy rating on the stock.

See today’s analyst top recommended stocks >>

The company has a one-year high of $5.13 and a one-year low of $1.60. Currently, Antares Pharma has an average volume of 872.6K.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Antares Pharma, Inc. is a combination drug device company, which engages in the development and commercialization of self-administered parenteral pharmaceutical products and technologies. Its proprietary products include XYOSTED injection, OTREXUP injection for subcutaneous use, and Sumatriptan injection. The company was founded in February 1979 and is headquartered in Ewing, NJ.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts